Decoy Therapeutics is trading 5.4% down at $1.58 on October 6, following a seven-session decline from $3.09 on September 25; no clear company-specific announcement explaining the move has been identified.
- Weakness follows recent steep declines and a reported biotech-sector downturn, while the broader U.S. market is higher.
- The September warrant inducement remains a potential dilution overhang, but available sources do not establish it as the direct cause of this session’s drop.